A

patient taking an experimental cancer drug from Kite Pharma died after experiencing severe brain swelling, the company said Monday.

The news sparked alarm on the heels of a series of patient deaths at competitor Juno Therapeutics, which is developing the same type of cutting-edge cancer immunotherapy, called CAR-T. The report may raise caution about the immunotherapy drugs that have sparked sky-high hopes even as their downsides have become increasingly apparent.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.